DNA Synthesis Market By Service (Oligonucleotide Synthesis, Standard Oligonucleotide Synthesis, Custom Oligonucleotide Synthesis, Gene Synthesis, Custom Gene Synthesis, and Gene Library Synthesis), By Method (Solid Phase Synthesis, PCR-based Enzyme Synthesis, and Chip-based DNA Synthesis), By Application (Research & Development, Diagnostics, and Therapeutics), By End-use (Biopharmaceutical Companies, Academic & Research Institutes, and Contract Research Organizations), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Report Overview

The DNA Synthesis Market Size is expected to be worth around USD 13.6 billion by 2033 from USD 3.2 billion in 2023, growing at a CAGR of 15.5% during the forecast period 2024 to 2033.

DNA synthesis has evolved from primarily a research-focused tool to becoming a cornerstone in clinical diagnostics. It provides valuable insights into the genetic basis of diseases, leading to more accurate diagnoses and personalized treatment approaches. In the field of cancer genomics, DNA synthesis helps characterize tumor genomic landscapes, identify driver mutations, and guide targeted therapies.

Additionally, synthetic biology relies heavily on custom gene synthesis for designing biological components and systems. The rise of gene therapy and genome editing technologies, such as CRISPR-Cas9, further emphasizes the need for custom gene synthesis. Researchers are encouraged to explore artificial gene synthesis for medical applications.

Programs like the Precision Medicine Initiative and advancements in companion diagnostic studies contribute to the growing adoption of expression analysis. For instance, in October 2023, Evonetix, one of the prominent market players, declared the DNA synthesis platform installation with a thermal controller and semiconductor chip at the Imperial College London to facilitate DNA synthesis in any lab for conducting disease and infection research.

Key Takeaways

• In 2023, the market for DNA synthesis generated a revenue of USD 3.2 billion, with a CAGR of 15.5%, and is expected to reach USD 13.6 billion by the year 2033.
• The service segment is divided into oligonucleotide synthesis, standard oligonucleotide synthesis, custom oligonucleotide synthesis, gene synthesis, custom gene synthesis, and gene library synthesis, with oligonucleotide synthesis taking the lead in 2023 with a market share of 54.8%.
• Considering the method, the market is divided into solid phase synthesis, PCR-based enzyme synthesis, and chip-based DNA synthesis. Among these, solid phase synthesis held a significant share.
• Furthermore, concerning the application segment, the market is segregated into research & development, diagnostics, and therapeutics. Research & Development sector stands out as the dominant player, holding the largest revenue share of 63.10% in the DNA synthesis market.
• The end-use segment is segregated into biopharmaceutical companies, academic & research institutes, and contract research organizations, with the biopharmaceutical companies segment leading the market, holding a substantial share.
• North America led the market by securing a market share of 39.7% in 2023.

Service Analysis

The oligonucleotide synthesis segment led in 2023, claiming a market share of 54.8% owing to its critical role in various applications, including genetic testing, synthetic biology, molecular diagnostics, and gene editing. They are synthesized with specific base pairs using nucleotide strands and primarily serve as primers and probes in biological processes.

The synthesis technique for oligonucleotides offers a swift and cost-effective way to produce desired sequences. As a result, there is a growing demand for these synthesized products. Automated synthesizers and high-throughput platforms have further fueled the expansion of the oligonucleotide synthesis market by enhancing efficiency and scalability.

Method Analysis

The solid phase synthesis held a significant share due to its efficiency and versatility. It allows the step-by-step construction of DNA sequences on solid supports, enabling precise nucleotide addition. The method ensures controlled and automated oligonucleotide synthesis, minimizing errors and maximizing yield.

Researchers and industries find it appealing for custom DNA production. Solid-phase synthesis is scalable and cost-effective, making it suitable for both research and industrial applications. Its widespread adoption solidifies its position in the market.

Application Analysis

The research & development segment had a tremendous growth rate, with a revenue share of 63.10% owing to the research and development (R&D) sector playing a crucial role in advancing biotechnology and pharmaceutical research.

It involves developing new DNA synthesis techniques, enhancing existing methodologies, and exploring novel applications of synthetic DNA. The increasing demand for custom DNA sequences for experimental studies, drug discovery, and genetic engineering drives the growth of DNA synthesis.

End-use Analysis

The biopharmaceutical companies segment grew at a substantial rate as biopharmaceutical companies increasingly adopt synthesized DNA products to develop innovative treatments for various diseases. These products offer targeted therapeutic options and contribute to market expansion. The segment’s growth is also fueled by regulatory approvals and the launch of gene-based therapies.

For instance, in January 2024, the US FDA approved Vertex Pharmaceuticals and CRISPR Therapeutics’ gene therapy for sickle cell disease, a rare blood disorder requiring regular transfusions. Overall, the biopharmaceutical sector continues to drive advancements in personalized medicine and disease management, creating demand for DNA synthesis products and services.

Key Market Segments

By Service

• Oligonucleotide synthesis
• Standard oligonucleotide synthesis
• Custom oligonucleotide synthesis
• Gene synthesis
• Custom gene synthesis
• Gene library synthesis

By Method

• Solid phase synthesis
• PCR-based enzyme synthesis
• CHIP-based DNA synthesis

By Application

• Research and Development
• Diagnostics
• Therapeutics

By End-use

• Biopharmaceutical companies
• Academic and research institutes
• Contract research organizations

Drivers

High Prevalence of Chronic Diseases

The rising prevalence of chronic diseases and growing awareness of personalized treatment options have led to increased usage and production of synthetic DNA products and services worldwide. For example, in 2024, the American Cancer Society estimated that 2,001,140 new cancer cases would occur in the U.S. This surge in cases necessitates early and precise diagnostic methods, driving the adoption of synthetic DNA services and products.

Over the past few decades, the demand for synthetic DNA has positively impacted the production of proteins, enzymes, and new drug discoveries. The adoption of synthetic biology for novel drugs and treatments further fuels the demand for synthetic DNA. Consequently, technologies delivering DNA with enhanced purity, greater quantity, and reduced costs have become a commercial priority, shifting away from isolating DNA from natural sources.

Restraints

High Cost of DNA Synthesis Products and Services

DNA synthesis involves intricate chemical reactions and requires advanced equipment. Multiple steps, including nucleotide coupling, purification, and deprotection, contribute to its complexity. These processes are time-consuming and resource-intensive. Additionally, the availability of high-quality raw materials (such as reagents and enzymes) impacts the overall cost.

Continuous advancements in DNA synthesis technologies necessitate significant investment in research and development (R&D). Companies focus on improving synthesis methods, increasing yield, and developing new chemistries all contributing to the overall cost of DNA synthesis.

Opportunities

Growing Popularity of Personalized Medicines

Personalized medicine tailors therapeutics to individual patients based on their genetic makeup. It draws insights from pharmacogenomics, pharmacogenetics, pharmacometabolomics, and pharmacoproteomics. By enhancing early detection, prevention, and therapy monitoring, personalized medicine aims to improve healthcare outcomes. Researchers use gene synthesis to create personalized treatments for patients with specific genetic variations or mutations.

DNA synthesis is integral to developing DNA-based diagnostic tests. These tests utilize synthetic DNA probes or primers to detect specific genetic sequences associated with diseases, pathogens, or genetic variations. The increasing demand for personalized medicine and precision diagnostics has fueled the growth of DNA-based diagnostics.

For instance, in June 2022, the Wexner Medical Center of Ohio State University (OSU) collaborated with Siemens Healthineers to advance personalized medicine. Their goal is to enhance access to cost-effective, high-quality healthcare using state-of-the-art imaging and treatment technologies at OSU’s patient care and research centers.

Impact of Macroeconomic / Geopolitical Factors

Macroeconomic and geopolitical factors exert a significant influence on the DNA synthesis market, shaping its growth trajectory and dynamics. Macroeconomic factors such as increased research & development funding drive the market by enabling innovation and application of synthetic biology applications. Geopolitical factors like trade tensions and export controls often limit access to DNA synthesis technologies and hinder market growth. However, strategic partnerships and collaborations among countries facilitate knowledge sharing and accelerate market development.

Latest Trends

Growing Use in Agriculture & Food Industry

DNA synthesis is used to engineer genetically modified (GM) crops with desirable traits. These traits include increased yield, enhanced disease resistance, improved nutritional content, and tolerance to environmental stresses. Scientists synthesize specific DNA sequences and introduce them into plant genomes, resulting in crops with targeted genetic modifications. Farming operations, such as crop cultivation, can alter DNA gene expression. DNA technology helps detect changes in gene expression levels, aiding in the regulation of crop development and growth.

Furthermore, DNA synthesis contributes to reducing the use of chemical pesticides. Biopesticides derived from natural sources are developed, minimizing environmental impact. Notably, the U.S. Department of Energy invested USD 178 million in bioenergy projects to advance sustainable technology, benefiting public health and improving agriculture and food production.

Regional Analysis

North America is leading the DNA Synthesis Market

North America dominated the market with the highest revenue share of 39.7% owing to the increasing prevalence of genetic and chronic diseases, along with the growing awareness for personalized treatments among patients and healthcare professionals. The rising demand for early diagnosis and precision medicine is driving the adoption of single-cell analysis products globally.

Notably, advancements in technology and significant investments from life sciences companies and government research initiatives contribute to this growth. For instance, in March 2024, Elegen’s recent advancement in ENFINIA DNA enables the delivery of high-complexity DNA within ten business days. Moreover, personalized medicine research and the need for tools facilitating single-cell analysis further fuel market expansion across various domains, including cancer research, immunology, and neuroscience

The Asia Pacific region is expected to experience the highest CAGR during the forecast period

Asia Pacific is expected to grow with the fastest CAGR during the forecast period. The region benefits from improving healthcare infrastructure and ongoing advancements in DNA-based molecular biology solutions. These developments create a conducive environment for DNA synthesis technologies. Rising investments in the establishment of new DNA manufacturing facilities drive market growth.

These facilities play a crucial role in meeting the demand for synthetic DNA products. Market players are actively collaborating with regional partners to expand synthetic DNA technologies. For instance, DNA Script’s distribution agreement in April 2022 with various companies across Asia, such as Premas Life Sciences Pvt. Ltd., Cold Spring Biotech Corp., Research Instruments Pte. Ltd., and Bio-Medical Science Co. Ltd., aims to enhance the presence of SYNTAX systems in the region. SYNTAX systems are the world’s first DNA printer that is driven by Enzymatic DNA Synthesis (EDS).

Key Regions and Countries

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Russia
  • Netherland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Australia
  • New Zealand
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of MEA

Key Players Analysis

The major players in the DNA synthesis market are actively engaged in the development and introduction of innovative products, as well as implementing strategic initiatives aimed at enhancing their competitive positioning. Numerous key players are investing heavily in the research and development to improve existing products and discover new applications. Collaborations with other companies, research institutions, and governments help players access new markets and technologies.

Top Key Players in the DNA Synthesis Market

• Thermo Fisher Scientific, Inc.
• Twist Bioscience
• Bioneer Corporation
• Eton Bioscience
• LGC Biosearch Technologies
• IBA GmbH
• Eurofins Scientific
• Integrated DNA Technologies, Inc.
• Quintara Biosciences
• GenScript Biotech Corporation
• OriGene Technologies, Inc.
• Eurogentec
• ProMab Biotechnologies
• BIOMATIK
• ProteoGenix
• BOSTER antibody
• ELISA experts

Recent Developments

• In May 2023, GenScript Biotech Corporation, one of the leading market players, launched chip-based GenTitan Gene Fragments services to fast-track gene synthesis in a cost-effective manner. This groundbreaking solution is anticipated to upscale the organization, pushing it ahead of the curve.
• In November 2023, Twist Bioscience launched Twist Express Genes, a gene synthesis service that offers genes in the range of 0.3 to 5.0kb with an accelerated shipping turnaround of 5 to 7 business days. Twist Bioscience is a biotechnology company from South San Francisco. It manufactures synthetic DNA as well as DNA products for a wide range of industries.

Report Scope